Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in type 1 diabetes before and after disease onset

S. A. Litherland, Jin-Xiong She, D. Schatz, K. Fuller, A. D. Hutson, R. H. Peng, Y. Li, K. M. Grebe, D. S. Whittaker, K. Bahjat, D. Hopkins, Q. Fang, P. D. Spies, K. North, C. Wasserfall, R. Cook, M. A. Dennis, S. Crockett, J. Sleasman, J. KocherA. Muir, J. Silverstein, M. Atkinson, M. J. Clare-Salzler

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Methods: We examined monocyte prostaglandin synthase 2 (PGS2/COX2) expression in individuals at risk for or with type 1 diabetes including: (i) 58 established type 1 and 2 diabetic patients; (ii) 34 autoantibody positive (AA+) children and adults; (iii) 164 infants and young children with insulin-dependent diabetes mellitus (IDDM) susceptibility human leukocyte antigen (HLA) alleles; and (iv) 37 healthy control individuals, over a 5-yr period. Results: Established type 1 diabetic patients (1 month to 30+ yr post-disease onset) had significantly higher PGS2 expression than healthy controls; by contrast, insulin-treated type 2 diabetic patients had significantly lower PGS2 expression than healthy controls. Longitudinal studies of AA+ subjects at risk for type 1 diabetes indicated that 73% (11/15) of individuals who developed this disease during the study period expressed high levels of PGS2 prior to or after onset. We also found high level PGS2 expression in genetically at-risk infants and young children that correlated with having a first-degree relative with type 1 diabetes, but not with age, gender, or HLA genotype. In this population, high level PGS2 expression coincided with or preceded autoantibody detection in 30% (3/10) of subjects. Conclusions: These findings suggest that high level monocyte PGS2 expression, although subject to fluctuation, is present in at-risk subjects at an early age and is maintained during progression to and after type 1 diabetes onset.

Original languageEnglish (US)
Pages (from-to)10-18
Number of pages9
JournalPediatric Diabetes
Volume4
Issue number1
DOIs
StatePublished - Mar 1 2003

Fingerprint

Prostaglandin-Endoperoxide Synthases
Type 1 Diabetes Mellitus
Monocytes
HLA Antigens
Autoantibodies
Longitudinal Studies
Alleles
Genotype
Insulin
Population

Keywords

  • Autoimmune disease
  • Cyclooxgenase 2
  • Monocyte
  • Prostaglandin
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Cite this

Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in type 1 diabetes before and after disease onset. / Litherland, S. A.; She, Jin-Xiong; Schatz, D.; Fuller, K.; Hutson, A. D.; Peng, R. H.; Li, Y.; Grebe, K. M.; Whittaker, D. S.; Bahjat, K.; Hopkins, D.; Fang, Q.; Spies, P. D.; North, K.; Wasserfall, C.; Cook, R.; Dennis, M. A.; Crockett, S.; Sleasman, J.; Kocher, J.; Muir, A.; Silverstein, J.; Atkinson, M.; Clare-Salzler, M. J.

In: Pediatric Diabetes, Vol. 4, No. 1, 01.03.2003, p. 10-18.

Research output: Contribution to journalArticle

Litherland, SA, She, J-X, Schatz, D, Fuller, K, Hutson, AD, Peng, RH, Li, Y, Grebe, KM, Whittaker, DS, Bahjat, K, Hopkins, D, Fang, Q, Spies, PD, North, K, Wasserfall, C, Cook, R, Dennis, MA, Crockett, S, Sleasman, J, Kocher, J, Muir, A, Silverstein, J, Atkinson, M & Clare-Salzler, MJ 2003, 'Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in type 1 diabetes before and after disease onset', Pediatric Diabetes, vol. 4, no. 1, pp. 10-18. https://doi.org/10.1034/j.1399-5448.2003.00042.x
Litherland, S. A. ; She, Jin-Xiong ; Schatz, D. ; Fuller, K. ; Hutson, A. D. ; Peng, R. H. ; Li, Y. ; Grebe, K. M. ; Whittaker, D. S. ; Bahjat, K. ; Hopkins, D. ; Fang, Q. ; Spies, P. D. ; North, K. ; Wasserfall, C. ; Cook, R. ; Dennis, M. A. ; Crockett, S. ; Sleasman, J. ; Kocher, J. ; Muir, A. ; Silverstein, J. ; Atkinson, M. ; Clare-Salzler, M. J. / Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in type 1 diabetes before and after disease onset. In: Pediatric Diabetes. 2003 ; Vol. 4, No. 1. pp. 10-18.
@article{e31770a56ef54413ae930eb75ee00338,
title = "Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in type 1 diabetes before and after disease onset",
abstract = "Methods: We examined monocyte prostaglandin synthase 2 (PGS2/COX2) expression in individuals at risk for or with type 1 diabetes including: (i) 58 established type 1 and 2 diabetic patients; (ii) 34 autoantibody positive (AA+) children and adults; (iii) 164 infants and young children with insulin-dependent diabetes mellitus (IDDM) susceptibility human leukocyte antigen (HLA) alleles; and (iv) 37 healthy control individuals, over a 5-yr period. Results: Established type 1 diabetic patients (1 month to 30+ yr post-disease onset) had significantly higher PGS2 expression than healthy controls; by contrast, insulin-treated type 2 diabetic patients had significantly lower PGS2 expression than healthy controls. Longitudinal studies of AA+ subjects at risk for type 1 diabetes indicated that 73{\%} (11/15) of individuals who developed this disease during the study period expressed high levels of PGS2 prior to or after onset. We also found high level PGS2 expression in genetically at-risk infants and young children that correlated with having a first-degree relative with type 1 diabetes, but not with age, gender, or HLA genotype. In this population, high level PGS2 expression coincided with or preceded autoantibody detection in 30{\%} (3/10) of subjects. Conclusions: These findings suggest that high level monocyte PGS2 expression, although subject to fluctuation, is present in at-risk subjects at an early age and is maintained during progression to and after type 1 diabetes onset.",
keywords = "Autoimmune disease, Cyclooxgenase 2, Monocyte, Prostaglandin, Type 1 diabetes",
author = "Litherland, {S. A.} and Jin-Xiong She and D. Schatz and K. Fuller and Hutson, {A. D.} and Peng, {R. H.} and Y. Li and Grebe, {K. M.} and Whittaker, {D. S.} and K. Bahjat and D. Hopkins and Q. Fang and Spies, {P. D.} and K. North and C. Wasserfall and R. Cook and Dennis, {M. A.} and S. Crockett and J. Sleasman and J. Kocher and A. Muir and J. Silverstein and M. Atkinson and Clare-Salzler, {M. J.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1034/j.1399-5448.2003.00042.x",
language = "English (US)",
volume = "4",
pages = "10--18",
journal = "Pediatric Diabetes",
issn = "1399-543X",
publisher = "Blackwell Munksgaard",
number = "1",

}

TY - JOUR

T1 - Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in type 1 diabetes before and after disease onset

AU - Litherland, S. A.

AU - She, Jin-Xiong

AU - Schatz, D.

AU - Fuller, K.

AU - Hutson, A. D.

AU - Peng, R. H.

AU - Li, Y.

AU - Grebe, K. M.

AU - Whittaker, D. S.

AU - Bahjat, K.

AU - Hopkins, D.

AU - Fang, Q.

AU - Spies, P. D.

AU - North, K.

AU - Wasserfall, C.

AU - Cook, R.

AU - Dennis, M. A.

AU - Crockett, S.

AU - Sleasman, J.

AU - Kocher, J.

AU - Muir, A.

AU - Silverstein, J.

AU - Atkinson, M.

AU - Clare-Salzler, M. J.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Methods: We examined monocyte prostaglandin synthase 2 (PGS2/COX2) expression in individuals at risk for or with type 1 diabetes including: (i) 58 established type 1 and 2 diabetic patients; (ii) 34 autoantibody positive (AA+) children and adults; (iii) 164 infants and young children with insulin-dependent diabetes mellitus (IDDM) susceptibility human leukocyte antigen (HLA) alleles; and (iv) 37 healthy control individuals, over a 5-yr period. Results: Established type 1 diabetic patients (1 month to 30+ yr post-disease onset) had significantly higher PGS2 expression than healthy controls; by contrast, insulin-treated type 2 diabetic patients had significantly lower PGS2 expression than healthy controls. Longitudinal studies of AA+ subjects at risk for type 1 diabetes indicated that 73% (11/15) of individuals who developed this disease during the study period expressed high levels of PGS2 prior to or after onset. We also found high level PGS2 expression in genetically at-risk infants and young children that correlated with having a first-degree relative with type 1 diabetes, but not with age, gender, or HLA genotype. In this population, high level PGS2 expression coincided with or preceded autoantibody detection in 30% (3/10) of subjects. Conclusions: These findings suggest that high level monocyte PGS2 expression, although subject to fluctuation, is present in at-risk subjects at an early age and is maintained during progression to and after type 1 diabetes onset.

AB - Methods: We examined monocyte prostaglandin synthase 2 (PGS2/COX2) expression in individuals at risk for or with type 1 diabetes including: (i) 58 established type 1 and 2 diabetic patients; (ii) 34 autoantibody positive (AA+) children and adults; (iii) 164 infants and young children with insulin-dependent diabetes mellitus (IDDM) susceptibility human leukocyte antigen (HLA) alleles; and (iv) 37 healthy control individuals, over a 5-yr period. Results: Established type 1 diabetic patients (1 month to 30+ yr post-disease onset) had significantly higher PGS2 expression than healthy controls; by contrast, insulin-treated type 2 diabetic patients had significantly lower PGS2 expression than healthy controls. Longitudinal studies of AA+ subjects at risk for type 1 diabetes indicated that 73% (11/15) of individuals who developed this disease during the study period expressed high levels of PGS2 prior to or after onset. We also found high level PGS2 expression in genetically at-risk infants and young children that correlated with having a first-degree relative with type 1 diabetes, but not with age, gender, or HLA genotype. In this population, high level PGS2 expression coincided with or preceded autoantibody detection in 30% (3/10) of subjects. Conclusions: These findings suggest that high level monocyte PGS2 expression, although subject to fluctuation, is present in at-risk subjects at an early age and is maintained during progression to and after type 1 diabetes onset.

KW - Autoimmune disease

KW - Cyclooxgenase 2

KW - Monocyte

KW - Prostaglandin

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=0038445226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038445226&partnerID=8YFLogxK

U2 - 10.1034/j.1399-5448.2003.00042.x

DO - 10.1034/j.1399-5448.2003.00042.x

M3 - Article

C2 - 14655518

AN - SCOPUS:0038445226

VL - 4

SP - 10

EP - 18

JO - Pediatric Diabetes

JF - Pediatric Diabetes

SN - 1399-543X

IS - 1

ER -